Arcus Biosciences, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Arcus Biosciences, Inc. (RCUS) reported Increase (Decrease) in Prepaid Expense and Other Assets of $2.15 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2022-11-02
- Arcus Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2022-09-30 was $6.18M.
- Arcus Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2022-06-30 was -$9.62M, a 312.88% decline year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2022-03-31 was $5.59M, a 22.37% increase year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2021-12-31 was $654.00K.
- Arcus Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2021 was $5.94M, a 609.31% increase from fiscal 2020.
- Arcus Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2020 was $838.00K, a 57.72% decline from fiscal 2019.
- Arcus Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2019 was $1.98M, a 67.97% increase from fiscal 2018.
- Arcus Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2018 was $1.18M, a 57.12% increase from fiscal 2017.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|---|
| 2022-09-30 | $6.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$3.44M derived: sum of 2 quarters · filed 2022-11-02 | $2.15M 10-Q · filed 2022-11-02 | $2.81M derived: sum of 4 quarters · filed 2022-11-02 | |
| 2022-06-30 | -$9.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$4.03M 10-Q · filed 2022-08-03 | -$3.37M derived: sum of 3 quarters · filed 2022-08-03 | -$7.17M derived: sum of 4 quarters · filed 2022-11-02 | |
| 2022-03-31 | $5.59M 10-Q · filed 2022-05-09 | $6.24M derived: sum of 2 quarters · filed 2022-05-09 | $2.45M derived: sum of 3 quarters · filed 2022-11-02 | $6.97M derived: sum of 4 quarters · filed 2022-11-02 | |
| 2021-12-31 | $654.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | -$3.14M derived: sum of 2 quarters · filed 2022-11-02 | $1.38M derived: sum of 3 quarters · filed 2022-11-02 | $5.94M 10-K · filed 2022-02-23 | |
| 2021-09-30 | -$3.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $722.00K derived: sum of 2 quarters · filed 2022-11-02 | $5.29M 10-Q · filed 2022-11-02 | -$778.00K derived: sum of 4 quarters · filed 2022-11-02 | |
| 2021-06-30 | $4.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $9.09M 10-Q · filed 2022-08-03 | $3.02M derived: sum of 3 quarters · filed 2022-08-03 | $5.32M derived: sum of 4 quarters · filed 2022-08-03 | |
| 2021-03-31 | $4.57M 10-Q · filed 2022-05-09 | -$1.50M derived: sum of 2 quarters · filed 2022-05-09 | $805.00K derived: sum of 3 quarters · filed 2022-05-09 | $1.70M derived: sum of 4 quarters · filed 2022-05-09 | |
| 2020-12-31 | -$6.07M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | -$3.76M derived: sum of 2 quarters · filed 2022-02-23 | -$2.87M derived: sum of 3 quarters · filed 2022-02-23 | $838.00K 10-K · filed 2022-02-23 | |
| 2020-09-30 | $2.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $3.20M derived: sum of 2 quarters · filed 2021-11-08 | $6.91M 10-Q · filed 2021-11-08 | $7.88M 10-Q · filed 2020-11-05 | $6.99M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $897.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $4.60M 10-Q · filed 2021-08-05 | $4.68M derived: sum of 3 quarters · filed 2022-02-23 | $5.63M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-03-31 | $3.70M 10-Q · filed 2021-05-05 | $3.78M derived: sum of 2 quarters · filed 2022-02-23 | $4.73M derived: sum of 3 quarters · filed 2022-02-23 | $4.93M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2019-12-31 | $80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $1.03M derived: sum of 2 quarters · filed 2022-02-23 | $1.22M derived: sum of 3 quarters · filed 2022-02-23 | $1.98M 10-K · filed 2022-02-23 | |
| 2019-09-30 | $950.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.14M derived: sum of 2 quarters · filed 2020-11-05 | $1.90M 10-Q · filed 2020-11-05 | $1.89M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $193.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $952.00K 10-Q · filed 2020-08-06 | $944.00K derived: sum of 3 quarters · filed 2021-02-25 | $1.72M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $759.00K 10-Q · filed 2020-05-05 | $751.00K derived: sum of 2 quarters · filed 2021-02-25 | $1.53M derived: sum of 3 quarters · filed 2021-02-25 | $1.25M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | -$8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $771.00K derived: sum of 2 quarters · filed 2021-02-25 | $487.00K derived: sum of 3 quarters · filed 2021-02-25 | $1.18M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $779.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $495.00K derived: sum of 2 quarters · filed 2019-11-05 | $1.19M 10-Q · filed 2019-11-05 | $651.00K derived: sum of 4 quarters · filed 2019-11-05 | |
| 2018-06-30 | -$284.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $409.00K 10-Q · filed 2019-08-06 | -$128.00K derived: sum of 3 quarters · filed 2019-08-06 | $794.00K derived: sum of 4 quarters · filed 2019-08-06 | |
| 2018-03-31 | $693.00K 10-Q · filed 2019-05-02 | $156.00K derived: sum of 2 quarters · filed 2019-05-02 | $1.08M derived: sum of 3 quarters · filed 2019-05-02 | $1.35M derived: sum of 4 quarters · filed 2019-05-02 | |
| 2017-12-31 | -$537.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $385.00K derived: sum of 2 quarters · filed 2019-03-05 | $655.00K derived: sum of 3 quarters · filed 2019-03-05 | $751.00K 10-K · filed 2019-03-05 | |
| 2017-09-30 | $922.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.19M derived: sum of 2 quarters · filed 2018-11-08 | $1.29M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $270.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $366.00K 10-Q · filed 2018-08-06 | |||
| 2017-03-31 | $96.00K 10-Q · filed 2018-05-09 | ||||
| 2016-12-31 | $602.00K 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |